Uncategorized

Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection

Published

2 weeks ago

on

Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December.

On Friday, the European Medicines Agency’s …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version